Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

121. Constipation: A Global Perspective

Constipation: A Global Perspective © World Gastroenterology Organisation, 2010 World Gastroenterology Organisation Global Guidelines Constipation: a global perspective November 2010 Review team Greger Lindberg (Chairman) Saeed Hamid (Pakistan) Peter Malfertheiner (Germany) Ole Thomsen (Denmark) Luis Bustos Fernandez (Argentina) James Garisch (South Africa) Alan Thomson (Canada) Khean-Lee Goh (Malaysia) Rakesh Tandon (India) Suliman Fedail (Sudan) Benjamin Wong (China) Aamir Khan (Pakistan (...) ) Justus Krabshuis (France) Anton Le Mair (The Netherlands) WGO Global Guideline Constipation 2 © World Gastroenterology Organisation, 2010 Contents 1 Introduction 3 1.1 Cascades—a resource-sensitive approach 3 2 Definition and pathogenesis 3 2.1 Pathogenesis and risk factors 3 2.2 Associated conditions and medications 4 3 Diagnosis 6 3.2 Diagnostic criteria for functional constipation 6 3.2 Patient evaluation 6 3.3 Alarm symptoms 7 3.4 Indications for screening tests 8 3.5 Transit measurement 8 3.6

World Gastroenterology Organisation2010

122. New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome

New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome 19228840 2009 03 31 2009 04 24 2016 11 22 1524-4628 40 4 2009 Apr Stroke Stroke New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome. 1304-9 10.1161/STROKEAHA.108.534776 The prevalence of constipation after stroke varies from 30% to 60%. The incidence of new-onset constipation during the early stage of stroke remains (...) uncertain. The present study was designed to investigate the prevalence of new-onset constipation, its risk factors, and its impact on stroke outcome in patients with their first stroke at acute stage. This is a prospective cohort study of 154 patients admitted with their first stroke. New-onset constipation during the first 4 weeks of stroke was recorded, using the Rome II criteria for constipation. Demographics, characteristics of the stroke, laboratory parameters, and use of medications were

EvidenceUpdates2009

123. Oxycodone / naloxone (Targinact) - Severe pain which can be adequately managed only with opioid analgesics. Naloxone is added to counteract opioid-induced constipation.

Oxycodone / naloxone (Targinact) - Severe pain which can be adequately managed only with opioid analgesics. Naloxone is added to counteract opioid-induced constipation.

Scottish Medicines Consortium2009

124. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study 19035970 2009 01 09 2009 04 02 2015 11 19 1365-2036 29 3 2009 Feb 01 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind (...) , placebo-controlled study. 315-28 10.1111/j.1365-2036.2008.03884.x Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, prucalopride, in patients with chronic constipation [

EvidenceUpdates2009

126. [Methylnaltrexone for opioid-induced constipation in cancer treatment]

[Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M. Metylnaltrekson ved forstoppelse i kreftbehandling. [Methylnaltrexone for opioid-induced constipation in cancer treatment] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 23 - 2009.. 2009 Authors' conclusions Our review suggests that methylnaltrexone was more effective than placebo in terms of time to laxation

Health Technology Assessment (HTA) Database.2009

127. Systematic review of Chinese herbal medicine for functional constipation

Systematic review of Chinese herbal medicine for functional constipation Systematic review of Chinese herbal medicine for functional constipation Systematic review of Chinese herbal medicine for functional constipation Cheng CW, Bian ZX, Wu TX CRD summary This review concluded that Chinese herbal medicine interventions or Chinese herbal medicines combined treatments showed benefit in the treatment of functional constipation when compared with cisapride, polyethylene glycol 4000, mosapride (...) , phenolphthalein, itopride and bifidobacteria alone, but not when compared with massage. The reliability of these conclusions is uncertain given the limited quality of included trials and other methodological concerns. Authors' objectives To assess the efficacy and safety of Chinese herbal medicine for the treatment of functional constipation. Searching The following databases were searched, without language restrictions, from 1994 to May 2009: MEDLINE, DARE, AMED, the Cochrane Library, ACP Journal Club

DARE.2009

128. Biofeedback therapy in fecal incontinence and constipation

Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Enck P, van der Voort IR, Klosterhalfen S CRD summary The authors concluded that there was evidence of a substantial therapeutic effect of biofeedback therapy for constipation due to pelvic floor dyssynergia, but lack of evidence for biofeedback therapy for incontinence. There were a number of limitations to this review (...) . In particular, the review did not report data specific to pelvic floor dyssynergia, so these conclusions may not be reliable. Authors' objectives To evaluate the efficacy of biofeedback therapy for the treatment of constipation and faecal incontinence. Searching PubMed was searched for studies published in English between 1980 and 2008; search terms were reported. In addition, reference lists in identified articles, reviews and meta-analyses were screened. Study selection Randomised controlled trials (RCTs

DARE.2009

130. Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited

Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited Article Text Treatment Review: high-quality evidence on the effectiveness of laxatives for functional constipation

Evidence-Based Nursing (Requires free registration)2009

131. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures

Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment (...) and dietary measures Pijpers MA, Tabbers MM, Benninga MA, Berger MY CRD summary The review found that there was insufficient evidence to show that laxatives were superior to placebo for treating constipation in children and that no one laxative could be recommended over any other. Although the review was limited in some respects, in particular the failure to address statistical heterogeneity, the authors' cautious conclusions appear justified. Authors' objectives To determine the effectiveness

DARE.2009

132. The use of naloxone for the treatment of opioid-induced constipation (OIC)

The use of naloxone for the treatment of opioid-induced constipation (OIC) "The use of naloxone for the treatment of opioid-induced constipation (" by Curtis Cole < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Rob Rosenow PharmD, OD Second Advisor Annjanette Sommers MS, PAC Rights . Abstract Background: Opioid-induced constipation (OIC) is a major problem that can have a significant impact (...) on a patient’s quality of life (QoL). The use of opioids for both long and short term analgesia has been the standard treatment for many years. All opioids, like oxycodone, can be connected with the development of bowel dysfunction, with constipation being one of the more frequently reported adverse effects. Many of the standard methods and protocols that hospitals use seem to have little effect on this continuing problem. Hypothesis: That the use of oral naloxone Prolonged Release (PR), in conjunction

Pacific University EBM Capstone Project2009

134. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial 18477346 2008 05 14 2008 05 30 2012 11 15 1572-0241 103 5 2008 May The American journal of gastroenterology Am. J. Gastroenterol. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. 1217-25 10.1111/j.1572-0241.2008.01808.x Though the greatest proportion of irritable bowel syndrome (IBS) patients report (...) a mixed bowel pattern (IBS-Mixed), no available therapies have been rigorously evaluated in this subgroup. This study aimed to evaluate the efficacy and safety of the 5-HT(4) agonist tegaserod in women with IBS-Mixed and IBS with constipation (IBS-C). This prospective, double-blind, randomized, placebo-controlled, multicenter study was conducted in 100 centers in North America, South America, and Europe. Women with IBS-Mixed or IBS-C received tegaserod 6 mg or placebo twice daily. The primary efficacy

EvidenceUpdates2008

135. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK

Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Guest J F, Clegg J P, Helter M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of macrogol 4000 compared with lactulose for the treatment of chronic functional constipation in adult patients. The authors concluded that macrogol 4000 was a cost-effective treatment from the perspective of the British National Health Service

NHS Economic Evaluation Database.2008

136. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom (...) relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M CRD summary This review evaluated the effectiveness of 5-hydroxytryptamine (serotonin) antagonists in treating irritable bowel syndrome (IBS). The authors concluded that 5-hydroxytryptamine antagonists significantly improved symptoms of non-constipated IBS and diarrhoea predominant IBS in men and women

DARE.2008

137. Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness

Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Article Text Therapeutics Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Statistics from Altmetric.com No Altmetric data available for this article. J Thomas Dr J Thomas, San Diego Hospice and Palliative Care

Evidence-Based Medicine (Requires free registration)2008

138. Daily polyethylene glycol over 6 months was effective for chronic constipation

Daily polyethylene glycol over 6 months was effective for chronic constipation Daily polyethylene glycol over 6 months was effective for chronic constipation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily polyethylene glycol over 6 months was effective for chronic constipation Article Text Therapeutics Daily polyethylene glycol over 6 months was effective for chronic constipation Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link

Evidence-Based Medicine (Requires free registration)2008

139. Behavioral therapy for childhood constipation: a randomized, controlled trial

Behavioral therapy for childhood constipation: a randomized, controlled trial 18450876 2008 05 02 2008 06 04 2008 05 02 1098-4275 121 5 2008 May Pediatrics Pediatrics Behavioral therapy for childhood constipation: a randomized, controlled trial. e1334-41 10.1542/peds.2007-2402 It has been suggested that the addition of behavioral interventions to laxative therapy improves continence in children with functional fecal incontinence associated with constipation. Our aim was to evaluate the clinical (...) effectiveness of behavioral therapy with laxatives compared with conventional treatment in treating functional constipation in childhood. In this randomized, controlled trial conducted in a tertiary hospital in The Netherlands, 134 children aged 4 to 18 years with functional constipation were randomly assigned to 22 weeks (12 visits) of either behavioral therapy or conventional treatment. Primary outcomes were defecation frequency, fecal incontinence frequency, and success rate. Success was defined

EvidenceUpdates2008

140. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting 18284648 2008 04 02 2008 07 10 2016 11 24 1365-2036 27 9 2008 May Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (...) . 830-7 10.1111/j.1365-2036.2008.03649.x Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required. To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort in patients with constipation-predominant irritable bowel syndrome. In this randomized, placebo-controlled, phase IIb study in the primary care setting

EvidenceUpdates2008